These genes, FOXA1, GATA3, and MYB, all showed greater mutation rates in ER+/luminal cancers relative to other breast cancer subtypes and, here, possessed up-regulated expression in early neoplasias relative to normal. This evidence concerns the gene GATA3 and cancer.